Rare Disease Contract Research Organization (CRO) Market Global Report 2026

The rare disease contract research organization (CRO) market size has grown strongly in recent years. It will grow from $2.07 billion in 2025 to $2.25 billion in 2026 at a compound annual growth rate (CAGR) of 8.6%. The growth in the historic period can be attributed to limited rare disease awareness restricting patient identification, fragmented clinical data systems limiting trial recruitment efficiency, high cost of orphan drug development reducing trial outsourcing scale, dependence on traditional site-based clinical research models, lack of standardized global rare disease regulatory frameworks.

The rare disease contract research organization (CRO) market size is expected to see strong growth in the next few years. It will grow to $3.16 billion in 2030 at a compound annual growth rate (CAGR) of 8.9%. The growth in the forecast period can be attributed to advancement in genomic sequencing enabling early rare disease detection, increasing orphan drug approvals driving CRO outsourcing demand, expansion of precision medicine accelerating niche clinical research, rising adoption of decentralized trials improving global patient access, growing biotech investment in rare disease therapeutics. Major trends in the forecast period include adaptive patient-centric trial designs for ultra-rare disease cohorts, expansion of global rare disease patient registry ecosystems, increased adoption of decentralized and hybrid rare disease clinical trials, growth of specialized orphan drug regulatory consulting services, rising integration of real-world evidence in rare disease clinical validation.

The expansion of gene and cell therapy pipelines is expected to drive the growth of the rare disease contract research organization market going forward. Gene and cell therapies are advanced treatment approaches that modify genes or utilize engineered cells to address diseases at their underlying cause. Gene and cell therapies are expanding primarily due to the increasing prevalence of chronic and rare genetic disorders, as these therapies provide targeted and potentially curative interventions by addressing the root genetic or cellular abnormalities rather than only managing symptoms. Rare disease contract research organizations (CROs) support gene and cell therapy by designing and managing highly specialized clinical trials, enabling efficient identification and recruitment of patients with rare genetic conditions, ensuring regulatory compliance, and managing the complex data and logistics required for these precision-based therapies. For instance, in March 2024, according to IQVIA Holdings Inc., a US-based provider of advanced analytics, technology solutions, and clinical research services for the life sciences and healthcare industries, global spending on cell and gene therapies reached $5.9 billion in 2023, representing a 38% increase from 2022. Therefore, the expansion of gene and cell therapy pipelines is driving the growth of the rare disease contract research organization market.

The growth in research and development activities is expected to drive the growth of the rare disease contract research organization (CRO) market going forward. Research and development (R&D) activities refer to work conducted to generate new knowledge and apply it to develop or improve products, services, or technologies. Rising research and development activities are driven by the increasing need for continuous innovation to remain competitive in rapidly evolving markets, prompting companies to invest in advanced products and technologies that address evolving consumer demands and industry trends. Rare disease contract research organizations (CROs) support research and development by providing specialized expertise, infrastructure, and patient recruitment capabilities that help accelerate the design, execution, and management of complex rare disease clinical trials and drug development programs. For instance, in 2023, according to the Office for National Statistics, a UK-based government agency, the UK government's net spending on research and development (R&D) increased to £17.4 billion ($22.1 billion) in 2023, up from £16.1 billion ($20.45 billion) in 2022, marking an 8.2% rise. Therefore, the growth in research and development activities is driving the growth of the rare disease contract research organization market.

In May 2023, Worldwide Clinical Trials, a US-based full-service contract research organization specializing in rare diseases, entered into a partnership with Every Cure to accelerate the discovery and advancement of therapies for patients with rare diseases through drug repurposing and clinical research support. The collaboration is intended to enhance rare disease treatment development by applying drug repurposing approaches, utilizing AI-driven data analytics, and increasing the efficiency of clinical trials. Every Cure is a US-based nonprofit organization dedicated to identifying new therapeutic uses for existing drugs.

Major companies operating in the rare disease contract research organization (cro) market are Thermo Fisher Scientific Inc., IQVIA Holdings Inc., Laboratory Corporation of America Holdings, ICON plc, SGS SA, Charles River Laboratories International Inc., Fortrea Holdings Inc., Medpace Holdings Inc., ALS Limited, PSI CRO AG, Ratos AB, Precision for Medicine Inc., Allucent, QPS Holdings LLC, Alira Health SAS, Rho Inc., Veristat LLC, Quanticate Ltd., Cromos Pharma LLC, Frontage Laboratories Inc., ProTrials Research Inc., PROMETRIKA LLC, Machaon Diagnostics Inc., Sofpromed GmbH.

North America was the largest region in the rare disease contract research organization (CRO) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rare disease contract research organization (CRO) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the rare disease contract research organization (CRO) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The rare disease contract research organization (CRO) market includes revenues earned by entities by providing services such as natural history studies, real-world evidence generation, biomarker research, and translational research support. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.